Harold Levy

Oppenheimer & Co., Inc. provides security brokerage services. It also offers investment banking and advice to high net worth investors, individuals, businesses and institutions. The company is headquartered in New York, NY.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA.

Part of LeadingSide, Inc., Sovereign Hill Software, Inc. supplies next generation software products. The company is based in Hadley, MA. Sovereign Hill Software was acquired by LeadingSide, Inc. on January 04, 1999 for $1.70 million.

Case Western Reserve University provides educational services. It offers a variety of undergraduate degree courses and graduate and professional options such as arts and sciences, dentistry, engineering, law, management, medicine, nursing, social work, and more. The firm also offers dual-degree programs. The company was founded in 1826 and is headquartered in Cleveland, OH.

Aspect Energy LLC operates as an exploration and energy investment company. The firm is engaged in oil and gas exploration and development efforts. The company was founded in 1992 and is headquartered in Denver, CO.

CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA.

Part of AstraZeneca PLC, AstraZeneca LP is a pharmaceutical company that focuses on developing and commercializing prescription drugs for various therapeutic areas. The company is based in Wilmington, DE.

ILKOS THERAPEUTICS, Inc. operates as biotechnology firm. It develops drug and clinical solutions for the treatment of venous lower limb ulcers. The company is headquartered in Laval, Canada.

Trieza Therapeutics, Inc. provides pharmaceutical services. It engages in the developing immunomodulatory oncolytic viruses for the treatment of cancer. The company is headquartered in Cambridge, MA.

Tvardi Therapeutics, Inc. develops and commercializes medicines for the treatment of diverse cancers, chronic inflammatory and fibrotic diseases. The company was founded by David J. Tweardy and Ronald A. DePinho in 2017 and is headquartered in Houston, TX.

Glyscend, Inc. engages in the development of therapeutics for treating metabolic diseases. It focuses on providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. The company was founded by Kevin Colbert in September 2014 and is headquartered in Baltimore, MD.

Boxcar PMJ LLC is an Independent Venture Capital firm founded in 2019 by Peter Feinberg. The firm is headquartered in the US.

Treadwell Therapeutics, Inc. operates as a clinical-stage oncology firm. It develops small molecules designed to leverage world-class, innovative science in cancer biology and immune-oncology with pan-cancer potential, including hematological malignancies from the TIO Discovery development engine. The company was founded by Tak Wah Mak and Mark R. Bray in July 2019 and is headquartered in New York, NY.

Tio Bioventures (Tio Bioventures) is a venture capital firm founded in 2019 by Tak Wah Mak and Shane Burgess. The firm is headquartered in New York.

Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts.

Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan.

Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen.

Sermonix Pharmaceuticals LLC operates as a pharmaceutical company that focuses on the development and commercialization of late-stage women?s health products. It offers lasofoxifene, a selective estrogen receptor modulator for the treatment of vulvovaginal atrophy, as well as treatment and prevention of post-menopausal osteoporosis. The company was founded in 2014 by David Portman and is headquartered in Columbus, OH.

Normunity, Inc. is a biotechnology company that creates precision immuno-oncology medicines called immune normalizers. The company is based in West Haven, CT and has subsidiaries in the United States. These medicines target novel mechanisms that free the body's normal immunity against cancer. Normunity is based on an ongoing academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. The CEO of the company is Rachel W. Humphrey.